Daniel J Canter
Overview
Explore the profile of Daniel J Canter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1045
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lerner S, Tangen C, Svatek R, Daneshmand S, Pohar K, Skinner E, et al.
N Engl J Med
. 2024 Nov;
391(13):1206-1216.
PMID: 39589370
Background: Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder cancer undergoing radical cystectomy is unclear. Methods:...
2.
Canter D, Canter D, Reidy P, Finucan T, Timmerman K
PM R
. 2023 Nov;
16(6):543-552.
PMID: 37950663
Background: Ambulation using standard axillary crutches (SACs) is associated with increased energy expenditure (EE) and decreased ability to perform activities of daily living (ADLs). Using a hands-free crutch (HFC) displays...
3.
Canter D, Branch C, Shelnutt J, Foreman A, Lehman A, Sama V, et al.
Adv Radiat Oncol
. 2023 May;
8(4):101193.
PMID: 37152483
Purpose: The objective of this study was to assess the association between the Oncotype DX Genomic Prostate Score (GPS) assay and long-term outcomes in men with localized prostate cancer (PCa)...
4.
Tward J, Schlomm T, Bardot S, Canter D, Scroggins T, Freedland S, et al.
Clin Genitourin Cancer
. 2021 Feb;
19(4):296-304.e3.
PMID: 33608228
Introduction: The combined clinical cell-cycle risk (CCR) score is a validated model that combines the cell-cycle progression (CCP) score with the University of California San Francisco Cancer of the Prostate...
5.
May D, Hill H, Matrana M, Lata-Arias K, Canter D
Urology
. 2020 Nov;
147:186-191.
PMID: 33203521
Objective: To examine the rates of adverse surgical outcomes in patients undergoing cytoreductive nephrectomy (CN) compared to patients undergoing radical nephrectomy in the nonmetastatic setting using a large administrative database....
6.
Smith S, Ghabra H, Dhaifallah D, Rahnema A, Evans B, Nossaman B, et al.
South Med J
. 2020 Oct;
113(10):499-504.
PMID: 33005965
Objectives: We postulated that an opiate-free (OF) general anesthesia (GA) technique could adequately control a patient's pain without adversely affecting recovery. We compared patients undergoing major urologic procedures with and...
7.
Modified Frailty Index Predicts Postoperative Outcomes in Patients Undergoing Radical Pelvic Surgery
McChesney S, Canter D, Monlezun D, Green H, Margolin D
Am Surg
. 2020 Mar;
86(2):95-103.
PMID: 32167059
Patients undergoing radical pelvic surgery such as proctectomy or radical cystectomy are at risk of experiencing a variety of complications. Frailty renders patients vulnerable to adverse events. We hypothesize that...
8.
Gurtner K, May D, Raman J, Lata-Arias K, Canter D
Can J Urol
. 2019 Oct;
26(5):9931-9937.
PMID: 31629442
Introduction: There has been growing use of adrenalectomy as a potentially curative treatment option for patients with oligometastatic disease to the adrenal gland. We sought to compare the perioperative outcomes...
9.
Alemozaffar M, Ogan K, Filson C, Patil D, Lee G, Canter D, et al.
Can J Urol
. 2019 Oct;
26(5):9908-9915.
PMID: 31629439
Introduction: The use of an electrocautery device (monopolar loop) for patients undergoing transurethral resection of bladder tumors (TURBT) is standard of care. The aim of this study is to establish...
10.
Judge S, Lata-Arias K, Yanagisawa M, Darrow M, Monjazeb A, Kirane A, et al.
J Surg Oncol
. 2019 Jul;
120(4):753-760.
PMID: 31355444
Background: Calls for multivisceral resection (MVR) of retroperitoneal sarcoma (RPS) are increasing, although the risks and benefits remain controversial. We sought to analyze current 30-day morbidity and mortality rates, and...